ES2079172T3 - Nuevo procedimiento de cristalizacion de sustancias organicas de origen esteroideo y compuestos asi obtenidos. - Google Patents

Nuevo procedimiento de cristalizacion de sustancias organicas de origen esteroideo y compuestos asi obtenidos.

Info

Publication number
ES2079172T3
ES2079172T3 ES92900237T ES92900237T ES2079172T3 ES 2079172 T3 ES2079172 T3 ES 2079172T3 ES 92900237 T ES92900237 T ES 92900237T ES 92900237 T ES92900237 T ES 92900237T ES 2079172 T3 ES2079172 T3 ES 2079172T3
Authority
ES
Spain
Prior art keywords
crystallization
solvent
organic substances
steroid
origin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92900237T
Other languages
English (en)
Inventor
Michel Lanquetin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Theramex SAM
Original Assignee
Laboratoire Theramex SAM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Theramex SAM filed Critical Laboratoire Theramex SAM
Application granted granted Critical
Publication of ES2079172T3 publication Critical patent/ES2079172T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO PROCESO DE CRISTALIZACION DE SUSTANCIAS ORGANICAS Y EN PARTICULAR ESTEROIDIANAS. LA PRESENTE INVENCION TIENE ESPECIFICAMENTE COMO OBJETO UN PROCESO DE CRISTALIZACION QUE PERMITE SIN OPERACION MECANICA OBTENER UNA CLASE GRANULOMETRICA HOMOGENEA PREDETERMINABLE, QUE CONSISTE EN QUE SE DISUELVE UNA SUSTANCIA EN UNA MEZCLA TERNARIA FORMADA POR UN SOLVENTE LIPOFILO, POR UN SOLVENTE HIDROFILO Y POR UN AGENTE TENSIOACTIVO A UNA TEMPERATURA CERCANA A LA EBULLICION DESPUES SE DEJA QUE LA MEZCLA VUELVA A UNA TEMPERATURA EN LA QUE LA CRISTALIZACION SE INICIA Y SEPARA LOS CRISTALES FORMADOS. PRODUCCION DE PRINCIPIOS ACTIVOS FARMACEUTICOS.
ES92900237T 1990-11-12 1991-11-12 Nuevo procedimiento de cristalizacion de sustancias organicas de origen esteroideo y compuestos asi obtenidos. Expired - Lifetime ES2079172T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013981A FR2668945B1 (fr) 1990-11-12 1990-11-12 Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.

Publications (1)

Publication Number Publication Date
ES2079172T3 true ES2079172T3 (es) 1996-01-01

Family

ID=9402062

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92900237T Expired - Lifetime ES2079172T3 (es) 1990-11-12 1991-11-12 Nuevo procedimiento de cristalizacion de sustancias organicas de origen esteroideo y compuestos asi obtenidos.

Country Status (17)

Country Link
US (1) US5266712A (es)
EP (1) EP0510167B1 (es)
JP (1) JP3281954B2 (es)
KR (1) KR100196895B1 (es)
AT (1) ATE126806T1 (es)
BR (1) BR9106012A (es)
CA (1) CA2073760C (es)
DE (1) DE69112379T2 (es)
DK (1) DK0510167T3 (es)
ES (1) ES2079172T3 (es)
FI (1) FI111545B (es)
FR (1) FR2668945B1 (es)
GR (1) GR3018117T3 (es)
HU (1) HU212780B (es)
LV (1) LV11183B (es)
RU (1) RU2126013C1 (es)
WO (1) WO1992008730A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
US6432936B1 (en) * 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
CA2418135C (en) 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
EP1591121B1 (en) * 2000-12-14 2009-06-24 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Process for preparing steroid hormone products comprising a stabilizing agent in non-crystalline form
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
CA2538856C (en) 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US20050192264A1 (en) * 2004-02-04 2005-09-01 Penfold Philip L. Slow release steroid composition
RU2253453C1 (ru) * 2004-03-15 2005-06-10 Общество с ограниченной ответственностью "ЮНАЛ" Противовоспалительная и антиаллергическая композиция
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20060058276A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for the preparation and purification of rocuronium bromide
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2655844A1 (en) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd. Process for preparing clopidogrel bisulphate
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
RU2740059C2 (ru) * 2012-06-18 2020-12-31 Терапьютиксмд, Инк. Капсулы с растворимым эстрадиолом для интравагинального введения
CN112871079B (zh) * 2021-01-27 2023-05-16 丽江映华生物药业有限公司 醋酸诺美孕酮微粒的制备方法及制备装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) * 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2361847A (en) * 1937-09-04 1944-10-31 Schering Corp Aromatization of steroid compounds and more especially to the production of estrone-and estradiollike compounds and of their derivatives from delta 1, 2, 4, 5-androstadienol-17-one-3
US2897216A (en) * 1954-11-01 1959-07-28 Schering Corp Process for the preparation of steroidal dienes and intermediates obtained thereby
US3053865A (en) * 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3836628A (en) 1972-05-22 1974-09-17 Int Research & Dev Co Ltd Crystal growth modifier
DE2323812A1 (de) * 1973-05-11 1974-11-28 Jenapharm Veb Verfahren zur herstellung von kohlensaeurederivaten der oestranreihe
GB1515284A (en) * 1974-05-21 1978-06-21 Gastaud J Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series
US4634694A (en) * 1984-01-14 1987-01-06 Akzo N.V. Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives
US4795747A (en) * 1985-12-23 1989-01-03 Latman Neal S 16-epiestriol to prevent, inhibit or reduce inflammation
US4956600A (en) * 1988-07-01 1990-09-11 Viteq Corporation High frequency current detector for a low frequency line

Also Published As

Publication number Publication date
CA2073760A1 (fr) 1992-05-13
LV11183A (lv) 1996-04-20
HUT61319A (en) 1992-12-28
BR9106012A (pt) 1993-01-05
KR100196895B1 (ko) 1999-06-15
FR2668945B1 (fr) 1993-02-19
FI111545B (fi) 2003-08-15
EP0510167B1 (fr) 1995-08-23
FR2668945A1 (fr) 1992-05-15
KR927003617A (ko) 1992-12-18
LV11183B (en) 1996-10-20
DK0510167T3 (da) 1996-01-02
RU2126013C1 (ru) 1999-02-10
US5266712A (en) 1993-11-30
HU212780B (en) 1996-11-28
HU9202608D0 (en) 1992-10-28
DE69112379T2 (de) 1996-03-28
DE69112379D1 (de) 1995-09-28
CA2073760C (fr) 2003-09-23
JPH05503305A (ja) 1993-06-03
JP3281954B2 (ja) 2002-05-13
EP0510167A1 (fr) 1992-10-28
ATE126806T1 (de) 1995-09-15
WO1992008730A1 (fr) 1992-05-29
GR3018117T3 (en) 1996-02-29
FI923188A0 (fi) 1992-07-10
FI923188L (fi) 1992-07-10

Similar Documents

Publication Publication Date Title
AR041932A1 (es) Derivados de ciclohexano espirociclicos, preparacion de los mismos, su uso en la fabricacion de medicamentos y dichos medicamentos.
Sartori et al. Highly effective synthesis of C-5-substituted 2′-deoxyuridine using Suzuki-Miyaura cross-coupling in water
Zaborsky et al. A Comparative Study of the Alkaline Hydrolysis of o-Hydroxy-α-toluenesulfonic Acid Sultone and Phenyl α-Toluenesulfonate
ES2067580T3 (es) N-acetilneuraminato de sodio.trihidrato y metodo para su preparacion.
Wenner 1, 2, 3, 4-Tetrahydroisoquinoline derivatives with antihypertensive properties
JPS5218489A (en) Process for production of carbon material
Redko et al. One-Pot Synthesis of 1, 4, 7, 10, 13, 16, 21, 24-Octaazabicyclo [8.8. 8] hexacosane-The Peraza Analogue of [2.2. 2] Cryptand
DK1765807T3 (da) Faste former af magnesiumsaltet af (S)-omeprazol og fremgangsmåder til fremstilling heraf
CO5580784A2 (es) Proceso para la reaccion de alcaloides y uso de los productos de reaccion en la preparacion de medicamentos
AR022737A1 (es) Procedimiento para la cristalizacion de n-(4-trifluorometilfenil)-5-metil-isoxazol-4-carboxamida
ES473901A1 (es) Procedimiento para preparar fosforoclorotionatos de dialqui-lo.
JPS54106478A (en) Preparation of 1, 3-dioxane derivative
DE3166683D1 (en) Solvate of amoxicillin, process for the preparation thereof and process for the preparation of injectable preparations from this solvate
Jones et al. The Action of Sodium Triphenylmethyl upon Trimethylmethoxyammonium Iodide and of Triphenylmethyl Halides upon TRIMETHYLAMINE1
GB953830A (en) A process for the resolution of racemic homocysteic acids
Fujita et al. Studies on the Alkaloids of Menispermaceous Plants (Masao Tomita). LXXXIII On the Structure of Biscoclaurine Alkaloids.(4). Cleavage of Cycleanine by Metallic Sodium in Liquid Ammonia
Eargle Jr et al. Electron paramagnetic resonance of detection of aryl ether cleavage II. The anion radicals of polyphenyl ethers
US3061406A (en) Process for the production of trifluoride of hypophosphorous acid and product thereof
Tomita et al. Studies on the Alkaloids of Magnoliaceous Plants. VIII Alkaloids of Magnolia denudata Desr.(1)
US2813096A (en) Method for producing dihydroisocodeine
JPS52102273A (en) Synthesis of 5-oxo-2-(alpha,alpha-disubstituted benzyloxyethyl)pyrrolidines
Tomita et al. Studies on the Alkaloids of Menispermaceae Plants. LXXX On the Structure of Biscoclaurine Alkaloids.(1). Cleavage of Isotetrandrine with Metallic Sodium in Liquid Ammonia and the Structure of Alkaloids in the Oxyacanthine-Berbamine Series
JPS549257A (en) Preparation of highly pure 1,8-dihydroanthraquinone
ES241397A1 (es) Procedimiento para la obtencion de novobiocina monosodica cristalina
Caldwell et al. A Synthesis of 4-Ethyl-6-aminopyrimidine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 510167

Country of ref document: ES